Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Patients with chronic obstructive pulmonary disease (COPD) who initiate treatment with inhaled corticosteroids (ICS) may have an elevated risk of developing type 2 diabetes mellitus (T2DM), according to a matched cohort study.
First-line treatment with durvalumab + platinum-etoposide (EP)* improves overall survival (OS) in Asian patients with extensive-stage small-cell lung cancer (ES-SCLC), according to the CASPIAN** study.
Adding pembrolizumab to platinum-based chemotherapy significantly improved survival and response to treatment compared with chemotherapy alone in the first-line setting for Chinese patients with metastatic, squamous non–small-cell lung cancer (NSCLC), according to the KEYNOTE-407* China Extension Study presented at the ESMO Asia 2019 Congress.
The ALK* inhibitor brigatinib maintained its superiority over crizotinib in the treatment of ALK+ non-small-cell lung cancer (NSCLC), according to the second interim results of the ALTA-1L** trial presented at ESMO Asia 2019.
The LAMA* aclidinium bromide was similarly effective in reducing exacerbation rate without raising the risk of MACE** or all-cause mortality regardless of recent history of exacerbations in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD), according to a subgroup analysis of the phase IV ASCENT-COPD*** trial presented at the CHEST 2019 Annual Meeting.
The lung damage acquired from smoking persists years after smoking cessation, with a faster decline in lung function in former smokers compared with never-smokers, according to a recent US-based study.
Consistent with clinical trial data, the use of biologic therapies significantly reduced asthma exacerbations in addition to having steroid-sparing effects in patients with severe, refractory asthma who were dependent on oral steroids, according to a real-world study presented at the annual CHEST Meeting 2019 held in New Orleans, Louisiana, US.
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.